Abstract
Objectives Although wood dust remains a leading cause of occupational asthma (OA) in Great Britain, there have been no recent studies in British woodworkers. This cross-sectional study examined asthma risk factors in woodworkers across exposure groups. Methods Participants answered a respiratory questionnaire and underwent fractional exhaled nitric oxide (FENO), spirometry, and specific immunoglobulin E measurements. Wood dust exposure was assigned through a specific job-exposure matrix. Multiple regression evaluated asthma risk factors identified a priori including wood dust exposure, atopy, and current asthma symptoms. Results A total of 269 woodworkers participated. Median wood dust exposure was 2.00mg/m3 (IQR 1.14 mg/m3). Current asthma symptoms (CAS), work-related respiratory symptoms (WRRS) and eosinophilic airway inflammation (FENO >40ppb) were common, present in 46%, 11% and 19% of the cohort, respectively. Atopic woodworkers were at increased risk of WRRS (OR 2.78, 95% CI 1.11 to 6.92, p<0.05), asthma (OR 3.40, 1.49 to 7.81, p<0.01), and FENO >40ppb (unadjusted OR 2.00, 1.03 to 3.88, p<0.05). No effect was seen for airflow obstruction. Workers with CAS were at increased risk of WRRS and ever asthma (4.29, 2.12 to 8.69, p<0.001) but not FENO >40ppb or airflow obstruction. Increasing exposure did not significantly increase risk of asthma symptoms, asthma, airflow obstruction and inflammation. Conclusions Asthma symptoms were prevalent among British woodworkers, even at low exposure levels. Atopy significantly increased asthma risk, particularly among symptomatic woodworkers. Further studies to phenotype and endotype populations of workers at risk of, and suffering from, wood dust OA will inform future approaches to screening and diagnosis in these populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Health and Safety Executive
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB NHS REC committee reference number 13/NI/0208 gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos